Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Nonclinical Development

November 11, 2025

Veteran drug development leader brings decades of expertise in advancing programs from discovery to clinical stage

BOSTON, November 11, 2025 —Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the appointment of Dennis Dean, Ph.D., as Executive Vice President and Head of Nonclinical Development.

In this role, **Dr. Dean** will lead all preclinical research and development activities that support the progression of Odyssey's drug candidates from discovery to clinical trials, including oversight of toxicology, drug metabolism and pharmacokinetics (DMPK), chemistry, manufacturing and controls (CMC), and program management. Dr. Dean will work closely with Discovery Research, Research Operations and Clinical Development to ensure Odyssey's nonclinical programs are scientifically rigorous, regulatory compliant, and strategically aligned with the company's advancing portfolio.

"Dennis joins Odyssey at a pivotal moment, as our lead programs advance toward later stages of development," said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. "His deep expertise in toxicology, pharmacology and translational sciences will be invaluable as we generate the data required to support clinical development, inform patient safety monitoring and prepare high-quality regulatory submissions. With his proven track record of guiding programs from discovery through IND* and into the clinic, Dennis is uniquely positioned to strengthen our nonclinical capabilities and help accelerate transformative medicines for patients."

Dr. Dean brings more than 25 years of experience spanning biotechnology and large pharmaceutical companies. Prior to joining Odyssey, he served as Chief Nonclinical Development Officer at Third Harmonic Bio, where he was responsible for leading the selection of high-quality development candidates, including toxicology, DMPK, and translation functions. Previously, Dr. Dean was Chief Development Officer at IFM Therapeutics, where he oversaw preclinical and clinical development, as well as advanced multiple programs into early clinical trials, which contributed to three successful acquisitions by global pharmaceutical companies. He was also Senior Vice President, Head of Preclinical Development at Vertex Pharmaceuticals, where he led translational groups including DMPK, preclinical safety assessment, clinical pharmacology, biomarkers, and modeling and simulation, working on the filings for approved medicines such as Telaprevir for Hepatitis C and Kalydeco and Orkambi for cystic fibrosis. Earlier in his career, he held positions of increasing responsibility in DMPK at Merck Research Laboratories.

Dr. Dean received his Ph.D. in medicinal chemistry from the State University of New York, Buffalo, and completed a postdoctoral fellowship in synthetic organic chemistry at Emory University. He has co-authored more than 90 publications and served in leadership roles within scientific societies and industry consortia.

"I was drawn to Odyssey because of its bold scientific vision and the opportunity to help shape transformative therapies from the ground up—something truly rare at this stage of my career," said Dr. Dean. "What excites me most is the caliber of the team and the chance to build a drug discovery and development platform that bridges cutting-edge science with real-world impact for patients."

*Investigational New Drug

About Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of completely internally discovered and developed medicines with the first reaching multiple clinical milestones in just over two years. The portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X and LinkedIn.